Patents by Inventor Kuang-Yuan Lee
Kuang-Yuan Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11661400Abstract: The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity.Type: GrantFiled: June 20, 2019Date of Patent: May 30, 2023Assignee: TAIWANJ PHARMACEUTICALS CO., LTD.Inventors: Syaulan S. Yang, Kuang Yuan Lee, Meng Hsien Liu, Yan-Feng Jiang, Yu-Shiou Fan, Chiung Wen Wang, Mei-Chi Hsu
-
Patent number: 11130771Abstract: A novel structure of an opioid antagonist is provided. One of the exemplary compounds of the present disclosure has the structure of Formula (II). The present disclosure overcomes the discomfort of conventional opioid antagonist due to rapid absorption and improves the patient compliance thereof.Type: GrantFiled: June 20, 2019Date of Patent: September 28, 2021Assignee: TAIWANJ PHARMACEUTICALS CO., LTD.Inventors: Syaulan S. Yang, Kuang Yuan Lee, Yan-Feng Jiang
-
Publication number: 20210276957Abstract: The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity.Type: ApplicationFiled: June 20, 2019Publication date: September 9, 2021Applicant: TAIWANJ PHARMACEUTICALS CO., LTD.Inventors: Syaulan S. YANG, Kuang Yuan LEE, Meng Hsien LIU, Yan-Feng JIANG, Yu-Shiou FAN, Chiung Wen WANG, Mei-Chi HSU
-
Publication number: 20210261579Abstract: A novel structure of an opioid antagonist is provided. One of the exemplary compounds of the present disclosure has the structure of Formula (II). The present disclosure overcomes the discomfort of conventional opioid antagonist due to rapid absorption and improves the patient compliance thereof.Type: ApplicationFiled: June 20, 2019Publication date: August 26, 2021Applicant: TAIWANJ PHARMACEUTICALS CO., LTD.Inventors: Syaulan S. YANG, Kuang Yuan LEE, Yan-Feng JIANG
-
Patent number: 11091421Abstract: The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): is a single or double bond; n is an integer of 0 or 1; A is —CH2—, —CH(OH)—, or —C(O)—; G is C or N; X is —CH2—, O, or —C(O)—; Y is alkyl, aryl, or heterocyclic alkyl optionally substituted with at least one substituent independently selected from a group consisting of: H, halogen, alkyl, alkyl substituted with at least one halogen, aryl, aryl substituted with at least one halogen, —NRy1Ry2, —ORy1, —Ry1C(O)Ry3, —C(O)Ry1, —C(O)ORy2, —C(O)ORy2Ry3, —NRy1C(O)Ry2, —NRy1C(O)NRy2Ry3, —NRy1C(O)ORy2Ry3, —NRy1C(O)Ry2ORy3, C(O)NRy1(Ry2Ry3), —C(O)NRy1(Ry2ORy1), —ORy2Ry3, and —ORy2ORy3, wherein each of Ry1 and Ry2 is independently selected from a group consisting of H, oxygen, alkyl, and aryl, and Ry3 is aryl optionally substituted with at least one halogen; Z is —NRz1Rz2, —NRz1Rz3, —ORz1, —ORz1Rz3, —C(O)Rz1Rz3, —C(O)ORz1Rz3, —NRz1C(O)Rz2Rz3, —NRz1C(O)ORz2Rz3, —C(O)NRz1Rz3, or ORz2ORz3, wherein each of Rz1 and Rz2 is independently selType: GrantFiled: September 7, 2018Date of Patent: August 17, 2021Assignee: TAIWANJ PHARMACEUTICALS CO., LTD.Inventors: Syaulan S. Yang, Kuang Yuan Lee, Meng Hsien Liu, Yan-Feng Jiang, Yu-Shiou Fan, Chi-Han Chen, Sheng Hung Liu
-
Publication number: 20210130316Abstract: Novel antagonists of toll-like receptor 4 (TLR-4) are provided. More specifically, the novel antagonists of TLR-4 are derived from morphinan. Further, use of said morphinan derivatives in the treatment of diseases and/or disorders mediated by TLR-4, such as autoimmune diseases, inflammation disease and infectious diseases, is provided. Pharmaceutical compositions including said morphinan derivatives are also provided.Type: ApplicationFiled: December 19, 2017Publication date: May 6, 2021Applicant: TAIWANJ PHARMACEUTICALS CO., LTDInventors: Syaulan S. YANG, Kuang-Yuan LEE, Edwin SC WU, Ming-Yu HSIAO, Hsiao-Chun WANG, Meng-Hsien LIU, Peter JS CHIU
-
Publication number: 20200247761Abstract: The present invention related to novel sulfonamides or amides as TLR-4 antagonists, and pharmaceutical formulations containing the same and the methods of use thereof. Uses of the present novel sulfonamides or amides include, but are not limited to, the prophylaxis and/or treatment of autoimmune, inflammation, or infection related disorders.Type: ApplicationFiled: January 25, 2018Publication date: August 6, 2020Applicant: TAIWANJ PHARMACEUTICALS CO., LTDInventors: Syaulan S. YANG, Kuang-Yuan LEE, Meng-Hsien LIU, Ming-Yu HSIAO, Huang-Kai PENG, Chiung-Wen WANG, Edwin SC WU, Peter JS CHIU
-
Publication number: 20200190010Abstract: The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): is a single or double bond; n is an integer of 0 or 1; A is —CH2—, —CH(OH)—, or —C(O)—; G is C or N; X is —CH2—, O, or —C(O)—; Y is alkyl, aryl, or heterocyclic alkyl optionally substituted with at least one substituent independently selected from a group consisting of: H, halogen, alkyl, alkyl substituted with at least one halogen, aryl, aryl substituted with at least one halogen, —NRy1Ry2, —ORy1, —Ry1C(O)Ry3, —C(O)Ry1, —C(O)ORy2, —C(O)ORy2Ry3, —NRy1C(O)Ry2, —NRy1C(O)NRy2Ry3, —NRy1C(O)ORy2Ry3, —NRy1C(O)Ry2ORy3, C(O)NRy1(Ry2Ry3), —C(O)NRy1(Ry2ORy1), —ORy2Ry3, and —ORy2ORy3, wherein each of Ry1 and Ry2 is independently selected from a group consisting of H, oxygen, alkyl, and aryl, and Ry3 is aryl optionally substituted with at least one halogen; Z is —NRz1Rz2, —NRz1Rz3, —ORz1, —ORz1Rz3, —C(O)Rz1Rz3, —C(O)ORz1Rz3, —NRz1C(O)Rz2Rz3, —NRz1C(O)ORz2Rz3, —C(O)NRz1Rz3, or ORz2ORz3, wherein each of Rz1 and Rz2 is independently selType: ApplicationFiled: September 7, 2018Publication date: June 18, 2020Applicant: TAIWANJ PHARMACEUTICALS CO., LTD.Inventors: Syaulan S. YANG, Kuang Yuan LEE, Meng Hsien LIU, Yan-Feng JIANG, Yu-Shiou FAN, Chi-Han CHEN, Sheng Hung LIU
-
Publication number: 20200157088Abstract: The present disclosure provides a benzene fused heterocyclic compound of Formula (I): wherein (A) is a single or double bond; n is 0 or 1; X is —CH2—, O, NR1, or S; A is —C(Ra1)(Ra2)(Ra3) or —N(Ra1)(Ra2), wherein Ra1, Ra2 and Ra3 are independently selected from a group consisting of: H, alkyl, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, C1-C3 hydrocarbon, —RaaORbb, —C(O)ORaaRbb, —C(O)RaaRbb, —C(O)NRaaRbb, —SO2 RaaRbb and —SO2 NRaaRbb which are optionally substituted by at least one substituent independently selected from a group consisting of: alkyl, cycloalkyl, heterocyclic alkyl, aryl, —Ybb, —ArbbYbb, —ORcc, and —OArbbYbb, wherein Raa, Rbb and Rcc independently are nil, H, halogen, alkyl, or aryl, Ybb is CN or halogen, and Araa and Arbb independently are aryl or heteroaryl; R1 is H or alkyl; R2 is alkyl, cycloalkyl, heterocylic alkyl, aryl, heteroaryl, C1-C6 hydrocarbon optionally substituted by at least one substituent independently selected from a group consisting of: —R2aOR2b, —R2aC(O)OR2bR2c, —R2aType: ApplicationFiled: November 30, 2018Publication date: May 21, 2020Applicant: TAIWANJ PHARMACEUTICALS CO., LTD.Inventors: Syaulan S. YANG, Kuang Yuan LEE, Yan-Feng JIANG, Yu-Shiou FAN, Meng Hsien LIU, Sheng Hung LIU, Jhih-Liang HUANG
-
Patent number: 8389560Abstract: This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.Type: GrantFiled: September 15, 2009Date of Patent: March 5, 2013Assignee: TaiGen Biotechnology Co., Ltd.Inventors: Chen-Fu Liu, Kuang-Yuan Lee, Pei-Chin Cheng, Yo-Chin Liu, Pin Lo, Kuo-Feng Tseng, Chih-Ming Chen, Chi-Hsin Richard King, Chu-Chung Lin
-
Publication number: 20110178107Abstract: This invention relates to compounds of Formula (I), (II), or (III) shown in the specification. These compounds can be used to treat hepatitis C virus infection.Type: ApplicationFiled: January 19, 2011Publication date: July 21, 2011Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Ching-Cheng Wang, Chen-Fu Liu, Kuang-Yuan Lee, Mei-Chun Lin, Shu-Huei Wang, Chi-Feng Yen, Yu-Hsuan Wang, Chi-Hsin Richard King
-
Publication number: 20110065737Abstract: This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.Type: ApplicationFiled: September 15, 2009Publication date: March 17, 2011Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Chen-Fu Liu, Kuang-Yuan Lee, Pei-Chin Cheng, Yo-Chin Liu, Pin Lo, Kuo-Feng Tseng, Chih-Ming Chen, Chi-Hsin Richard King, Chu-Chung Lin
-
Publication number: 20090286814Abstract: This invention relates to macrocyclic compounds of formula (I) or (II) shown in the specification. These compounds can be used to treat hepatitis C virus infection.Type: ApplicationFiled: November 4, 2008Publication date: November 19, 2009Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Chu-chung Lin, Kuang-Yuan Lee, Yo-chin Liu, Pin Lo, Rong-Jiunn Chen, Chen-Fu Liu, Chih-Ming Chen, Chi-Hsin Richard King
-
Publication number: 20090111757Abstract: Compounds of formula (I): in which R1, R2, R3 R4, and R5, U, X, Y, and Z are as defined herein. Also disclosed is use of these compounds, alone or in combination with other active agents, to treat hepatitis C virus infection.Type: ApplicationFiled: October 20, 2008Publication date: April 30, 2009Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Chu-Chung Lin, Kuang-Yuan Lee, Chen-Fu Liu, Pin Lo, Yo-Chin Liu, Yueh-chiang Han, Chi-Hsin Richard King
-
Publication number: 20080207528Abstract: This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat hepatitis C virus infection.Type: ApplicationFiled: January 31, 2008Publication date: August 28, 2008Inventors: Syaulan Yang, Kuang-Yuan Lee, Rong-Juinn Chen, Pin Lo, Shao-Ying Liao, Jen-Dar Wu, Chi-Hsin Richard King
-
Publication number: 20060036093Abstract: This invention relates to treating inflammatory and immune diseases with certain pyrimidinone compounds that bind to CXCR3 receptors. The pyrimidinone compounds are covered by the formula (I) shown below. Each variable is defined in the specification.Type: ApplicationFiled: August 16, 2005Publication date: February 16, 2006Inventors: Chu-Chung Lin, Hong-Chuan Chen, Kuang-Yuan Lee, Ying-Huey Huang, Yang-Ping Fan, Yibin Xiang